Trial reportIndian journal of pediatrics2012
Efficacy and safety of Saccharomyces boulardii in acute childhood diarrhea: a double blind randomised controlled trial.
Trial report in Indian journal of pediatrics, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Effectiveness and Safety of Saccharomyces Boulardii for the Treatment of Acute Gastroenteritis in the Pediatric Population: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.Computational and mathematical methods in medicine · 2022Pooled it
- Probiotics for treating acute infectious diarrhoea.The Cochrane database of systematic reviews · 2020Pooled it
- AGA Technical Review on the Role of Probiotics in the Management of Gastrointestinal Disorders.Gastroenterology · 2020Guideline
- A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Saccharomyces boulardii in Infants and Children With Acute Diarrhea.The Pediatric infectious disease journal · 2020Trial
- Saccharomyces boulardii and bismuth subsalicylate as low-cost interventions to reduce the duration and severity of cholera.Pathogens and global health · 2015Trial
- A double blind randomized trial showing probiotics to be ineffective in acute diarrhea in Indonesian children.Indian journal of pediatrics · 2015Trial
- Lactobacillus GG for treatment of acute childhood diarrhoea: an open labelled, randomized controlled trial.The Indian journal of medical research · 2014Trial
- Safety and efficacy concerns in Indian probiotics: Insights from whole-genome sequencing andGut microbes reports · 2026Article
- Pathogen-Specific Benefits of Probiotic and Synbiotic Use in Childhood Acute Gastroenteritis: An Updated Review of the Literature.Nutrients · 2023Review
- Efficacy of probiotics in the treatment of acute diarrhea in children: a systematic review and meta-analysis of clinical trials.Translational pediatrics · 2021Article
- Which Probiotic Is the Most Effective for Treating Acute Diarrhea in Children? A Bayesian Network Meta-Analysis of Randomized Controlled Trials.Nutrients · 2021Article
- Specific Probiotics for the Treatment of Pediatric Acute Gastroenteritis in India: A Systematic Review and Meta-Analysis.JPGN reports · 2021Review
- Modulatory Effects of Probiotics During Pathogenic Infections With Emphasis on Immune Regulation.Frontiers in immunology · 2021Review
- Retrospective analysis of EMR database to assess the effectiveness ofNew microbes and new infections · 2020Article
- Therapeutic effect ofExperimental and therapeutic medicine · 2019Article
- The global problem of childhood diarrhoeal diseases: emerging strategies in prevention and management.Therapeutic advances in infectious disease · 2018Review
- Complete genome sequence and comparative genomics of the probiotic yeast Saccharomyces boulardii.Scientific reports · 2017Article
- Saccharomyces Boulardii in Helicobacter Pylori Eradication in Children: A Randomized Trial From Iran.Iranian journal of pediatrics · 2016Article
- Probiotics and prebiotics in infants and children.Current infectious disease reports · 2013Article
- Generation of a Uracil Auxotroph Strain of the Probiotic Yeast Saccharomyces boulardii as a Host for the Recombinant Protein Production.Avicenna journal of medical biotechnology · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo see the efficacy and safety of 250 mg of Saccharomyces boulardii twice daily for 5 d in acute childhood diarrhea.
methodsChildren aged between 3 mo and 59 mo with acute onset diarrhea (of less than 48 h) admitted in DTTU (diarrhea treatment and training unit) were included and those with clinical evidence of severe malnutrition, systemic infection, encephalopathy and/or convulsion, electrolyte imbalance, invasive diarrhea or previous use of any probiotics were excluded from the study. Those included randomly were given either a placebo or Saccharomyces boullardi (SB) in identical packets mixed with puffed rice powder.
resultsMean post intervention duration of diarrhea was significantly (95% CI = -28.13 to -5.43) shorter in SB group (52.08 ± 24.57 h) as compared to placebo group (64.04 ± 30.43 h). The time of appearance of first semi formed stool in SB group (39.48 ± 23.09 h) was significantly (95% CI -25.4 to -3.87) shorter than the placebo group (54.13 ± 28.21 h). No statistically significant difference was found in rest of the parameters.
conclusionsThere is initial evidence available that SB may have a therapeutic role in the management of acute childhood diarrhea.
Indexed as
Identifiers
21997865What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.